

Sharing knowledge and partnering for the future

Delivering social and economic benefits to Canadians

In its bid to identify new opportunities for knowledge and technology transfer, AllerGen NCE Inc. has partnered with more than 100 organizations spanning multiple jurisdictions including Canada, the United States, Australia, the United Kingdom and Europe during its first two years of operation.

Through the initiation of pan-Canadian partnerships connecting excellent research with business leaders, industry entrepreneurs, policy makers, healthcare providers and patient advocates, the Network focuses its efforts and resources on research and development that will reduce the impact of allergy, asthma and anaphylaxis nationally and globally. These partnerships underpin AllerGen's ability to translate Network research into economic and social benefits for Canadians.

AllerGen is committed to achieving the following strategic objectives in the areas of knowledge and technology exchange and exploitation:

1. Accelerate exchange of research results within the Network.
AllerGen facilitates the creation of products, team-building and networking activities that result in the sharing of best practices, research innovations, innovations in methodology, and research approaches developed by cross-fertilization of disciplines.
2. Accelerate the exchange of research results beyond the Network.
AllerGen investigators and partners attend Network-hosted meetings, workshops and an annual research conference, in addition to externally hosted lectures, workshops and events. AllerGen-funded research informs many areas, including clinical practice, prevention strategies and public policy.
3. Use Network-generated knowledge for technology or market development for the benefit of the Canadian economy.
AllerGen-supported research, such as the Clinical Investigator Collaborative (CIC), focuses on discovery and development of new therapeutics to treat allergic disease. The CIC provides a cost-effective clinical trials service to help fast-track new drug entities.
4. Use Network-generated knowledge for public policy development and social program delivery for the benefit of Canadians.
AllerGen invests in the development of research partnerships with public policy makers like Health Canada, Environment Canada, Workers Compensation Boards and federal and provincial ministries of education. Research is actively disseminated to clinicians and health care providers to improve disease management and quality of life for allergic disease sufferers.
5. Manage and protect intellectual property arising from Network-supported research.
AllerGen-supported IP translates into new products and services with social and/or commercial value. The Network has ten disclosures to date.